Please wait...

Learn

Finding accredited CPD

Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes

Description

While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.

This MJA narrative review shares more.

Learning Outcomes

  1. Explain key components of the review
  2. List main recommendations
  3. Recognise changes in management as a result of the review.

Details

Authors: Renata Libianto, Timothy ME Davis, Elif I Ekinci

Article Type: Narrative review

 

Provided by

CPD Activity Details
Topic
Pharmaceutical Preparations, Cardiovascular Diseases, Endocrine System Diseases
CAPE Aspects
_
Effective Year

Educational Activities (EA) - 1.0

Reviewing Performance (RP) - 0.0

Measuring Outcomes (MO) - 0.0

You have to log in to see the content of this module.

*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)